SMALL BUSINESS PROGRAMS AT THE NATIONAL INSTITUTE ON DRUG ABUSE

Office of Translational Initiatives and
Program Innovation (OTIPI),
Office of Director,
National Institute on Drug Abuse (NIDA)

Elena Koustova, PhD, MBA

NIH
National Institute on Drug Abuse

DISCLOSURE STATEMENT

- I have no real or apparent relevant financial relationships to disclose
- The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to or any organization with which the presenter is employed or affiliated

AN INVESTOR OF FIRST RESORT: THE STATE

3.2%

(FY22)

SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM

Set-aside program for small business concerns to engage in federal R&D - with potential for commercialization

0.45%

(FY22)

SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM

Set-aside program to facilitate cooperative R&D between small business concerns and US research institutions - with potential for commercialization

SBIR/STTR FEDERAL AGENCIES

USDA · CDC · DARPA · DHA · NASA · NIST

genzyme · CHIRON · affymetrix · biogen idec · COMPAQ · illumina · 23andMe · iRobot · intel · QUALCOMM

>$50mil



Over $1.2 bil

To seek **fundamental knowledge** about the nature and behavior of living systems

The only present way to bring scientific discoveries to the patients is to subject them to business practices and market forces

The **application of** that **knowledge** to enhance health, lengthen life, and reduce illness and disability

SBIR Grants: Success Rates of Competing Applications, by Phase





Open Funding Opportunities



	SBIR	STTR
Partnering Requirement	Permits partnering	Requires a non-profit research institution partner (e.g., university)
Work Requirement	Guidelines: May outsource 33% (Phase I) 50% (Phase II)	Minimum Work Requirements: 40% small business 30% research institution partner
Principal Investigator	Primary employment (>50%) must be with the small business	PI may be employed by either the research institution partner or small business

General Grant Omnibus Solicitations

Clinical Trial Not Allowed:
SBIR (PA-22-176) and STTR (PA-22-178)
Clinical Trials Required:
SBIR (PA-22-177) and STTR (PA-22-179)

Targeted Solicitations

- Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)

SBIR (RFA-DA-23-021) (Clinical trial optional)
Due date: August 25, 2023; February 14, 2024; August 13, 2024; February 14, 2025
Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II

- Blueprint MedTech: Small Business Translator

SBIR (PAR-21-282) (Clinical trial optional)
Due date: June 20, 2023; October 18, 2023; February 20, 2024; and June 20, 2024 Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II

- Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System

SBIR (PAR-20-111) (Clinical trial optional)
Due date: February 9, 2023.
Award Budget: Up to $320,000 for Phase I, and $2.5 million for Phase II

Portfolio Companies - 164

SBIR grants - 156
STTR grants - 36



SPARK BIOMEDICAL

1R43DA050360-03

Transcutaneous auricular neuro-stimulation for neonatal abstinence syndrome

prapela

5R44DA049300-03

Prapela™ SVS: A cost-effective stochastic vibrotactile stimulation device to improve the clinical course of infants with neonatal abstinence syndrome.



https://www.hhs.gov/overdose-prevention/



invistics

S:3 Research

appliedVR

SOUND life sciences

BIO BOT Biobot Analytics

Workit Health

Sober Grid

Woebot

village

emocha MOBILE HEALTH INC.

prapela

we the Village

Marigold HEALTH

Primary Prevention

AppliedVR



2019: R44 DA049640-02 Virtual Reality as an Opioid Sparing Intervention for Acute Postoperative Pain Management

- October 2020: Receives FDA Breakthrough Device Designation to Treat Pain with Digital Therapeutic
- November 2021: Receives FDA De Novo clearance for treating chronic lower back pain





Indication for Use

RelieVRx is a prescription-use immersive virtual reality system intended to provide adjunctive treatment based on cognitive behavioral therapy skills and other evidence-based behavioral methods for patients (age 18 and older) with a diagnosis of chronic lower back-pain (defined as moderate to severe pain lasting longer than three months). The device is intended for in-home use for the reduction of pain and pain interference associated with chronic lower back pain.

Contraindications
There are no known contraindications.

Connect



https://nida.nih.gov/funding/small-business-innovation-research-sbir-technology-transfer-sttr-programs

nidasbir@mail.nih.gov